PMID- 33195144
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201117
IS  - 2296-4185 (Print)
IS  - 2296-4185 (Electronic)
IS  - 2296-4185 (Linking)
VI  - 8
DP  - 2020
TI  - Modifying and Integrating in vitro and ex vivo Respiratory Models for Inhalation 
      Drug Screening.
PG  - 581995
LID - 10.3389/fbioe.2020.581995 [doi]
LID - 581995
AB  - For the past 50 years, the route of inhalation has been utilized to administer 
      therapies to treat a variety of respiratory and pulmonary diseases. When compared 
      with other drug administration routes, inhalation offers a targeted, non-invasive 
      approach to deliver rapid onset of drug action to the lung, minimizing systemic 
      drug exposure and subsequent side effects. However, despite advances in inhaled 
      therapies, there is still a need to improve the preclinical screening and the 
      efficacy of inhaled therapeutics. Innovative in vitro models of respiratory 
      physiology to determine therapeutic efficacy of inhaled compounds have included 
      the use of organoids, micro-engineered lung-on-chip systems and sophisticated 
      bench-top platforms to enable a better understanding of pulmonary mechanisms at 
      the molecular level, rapidly progressing inhaled therapeutic candidates to the 
      clinic. Furthermore, the integration of complementary ex vivo models, such as 
      precision-cut lung slices (PCLS) and isolated perfused lung platforms have 
      further advanced preclinical drug screening approaches by providing in vivo 
      relevance. In this review, we address the challenges and advances of in vitro 
      models and discuss the implementation of ex vivo inhaled drug screening models. 
      Specifically, we address the importance of understanding human in vivo pulmonary 
      mechanisms in assessing strategies of the preclinical screening of drug efficacy, 
      toxicity and delivery of inhaled therapeutics.
CI  - Copyright (c) 2020 Cidem, Bradbury, Traini and Ong.
FAU - Cidem, Aylin
AU  - Cidem A
AD  - Respiratory Technology, Woolcock Institute of Medical Research, Sydney, NSW, 
      Australia.
FAU - Bradbury, Peta
AU  - Bradbury P
AD  - Respiratory Technology, Woolcock Institute of Medical Research, Sydney, NSW, 
      Australia.
AD  - Faculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia.
FAU - Traini, Daniela
AU  - Traini D
AD  - Respiratory Technology, Woolcock Institute of Medical Research, Sydney, NSW, 
      Australia.
AD  - Faculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia.
FAU - Ong, Hui Xin
AU  - Ong HX
AD  - Respiratory Technology, Woolcock Institute of Medical Research, Sydney, NSW, 
      Australia.
AD  - Faculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20201023
PL  - Switzerland
TA  - Front Bioeng Biotechnol
JT  - Frontiers in bioengineering and biotechnology
JID - 101632513
PMC - PMC7644812
OTO - NOTNLM
OT  - drug delivery
OT  - drug efficacy
OT  - drug toxicity
OT  - inhalation therapy
OT  - isolated perfused lung
OT  - lung-on-chip
OT  - organoid
OT  - precision-cut lung slices
EDAT- 2020/11/17 06:00
MHDA- 2020/11/17 06:01
PMCR- 2020/01/01
CRDT- 2020/11/16 08:54
PHST- 2020/07/10 00:00 [received]
PHST- 2020/10/06 00:00 [accepted]
PHST- 2020/11/16 08:54 [entrez]
PHST- 2020/11/17 06:00 [pubmed]
PHST- 2020/11/17 06:01 [medline]
PHST- 2020/01/01 00:00 [pmc-release]
AID - 10.3389/fbioe.2020.581995 [doi]
PST - epublish
SO  - Front Bioeng Biotechnol. 2020 Oct 23;8:581995. doi: 10.3389/fbioe.2020.581995. 
      eCollection 2020.